Kamada Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Kamada Ltd., a foreign private issuer, covers the month of July 2026. The report was filed on July 20, 2026, and incorporates by reference into the company's Form S-8 Registration Statements.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics for the reporting period. The document focuses exclusively on a material corporate agreement.
Material Changes and Corporate Developments
The primary material event disclosed is a new three-year sales agreement to supply plasma to a leading biopharmaceutical company focused on plasma-derived therapies. The total value of this agreement is $50 million.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, specific risk factors, or details on contingencies beyond the announcement of the new supply contract.
Key Facts for Investor Verification
- Confirmation of the $50 million total value of the three-year plasma supply agreement.
- Identification of the specific biopharmaceutical company partner.
- Details regarding the revenue recognition schedule and payment terms of the agreement.
- Impact of this agreement on Kamada's future cash flow and production capacity.